| Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review CF Friedman, TA Proverbs-Singh, MA Postow JAMA oncology 2 (10), 1346-1353, 2016 | 837 | 2016 |
| Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study M Javle, MJ Borad, NS Azad, R Kurzrock, GK Abou-Alfa, B George, ... The lancet oncology 22 (9), 1290-1300, 2021 | 259 | 2021 |
| Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma AN Shoushtari, CF Friedman, P Navid-Azarbaijani, MA Postow, ... JAMA oncology 4 (1), 98-101, 2018 | 151 | 2018 |
| Clinical utility of prospective molecular characterization in advanced endometrial cancer TE Soumerai, MTA Donoghue, C Bandlamudi, P Srinivasan, MT Chang, ... Clinical Cancer Research 24 (23), 5939-5947, 2018 | 129 | 2018 |
| Combinatorial cancer immunotherapies MD Hellmann, CF Friedman, JD Wolchok Advances in immunology 130, 251-277, 2016 | 120 | 2016 |
| Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma S Rosner, E Kwong, AN Shoushtari, CF Friedman, AS Betof, MS Brady, ... Cancer medicine 7 (3), 690-697, 2018 | 104 | 2018 |
| Ovarian cancer mutational processes drive site-specific immune evasion I Vázquez-García, F Uhlitz, N Ceglia, JLP Lim, M Wu, N Mohibullah, ... Nature 612 (7941), 778-786, 2022 | 97 | 2022 |
| Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab+ ipilimumab CF Friedman, V Clark, AV Raikhel, T Barz, AN Shoushtari, P Momtaz, ... JNCI: Journal of the National Cancer Institute 109 (4), djw260, 2017 | 72 | 2017 |
| Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer CF Friedman, AS Charen, Q Zhou, MA Carducci, AB De Meritens, BR Corr, ... Journal for immunotherapy of cancer 8 (2), 2020 | 63 | 2020 |
| Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). CF Friedman, TZ Horvat, J Minehart, K Panageas, MK Callahan, ... Journal of Clinical Oncology 34 (15_suppl), 10009-10009, 2016 | 53 | 2016 |
| MyPathway HER2 basket study: pertuzumab+ trastuzumab treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors F Meric-Bernstam, J Hainsworth, R Bose J Clin Oncol 39 (15_suppl), 3004, 2021 | 52 | 2021 |
| Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer M Stasenko, I Tunnage, CW Ashley, MM Rubinstein, AJ Latham, ... Gynecologic oncology 156 (1), 194-202, 2020 | 52 | 2020 |
| Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers H Veeraraghavan, CF Friedman, DF DeLair, J Ninčević, Y Himoto, ... Scientific reports 10 (1), 17769, 2020 | 51 | 2020 |
| Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition CF Friedman, MA Postow Current oncology reports 18, 1-7, 2016 | 50 | 2016 |
| Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study CF Friedman, JD Hainsworth, R Kurzrock, DR Spigel, HA Burris III, ... Cancer discovery 12 (3), 654-669, 2022 | 49 | 2022 |
| Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial A Oaknin, CF Friedman, LD Roman, A D'Souza, I Brana, FC Bidard, ... Gynecologic oncology 159 (1), 150-156, 2020 | 48 | 2020 |
| Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade JL Boland, Q Zhou, M Martin, MK Callahan, J Konner, RE O'Cearbhaill, ... Gynecologic oncology 152 (2), 251-258, 2019 | 40 | 2019 |
| BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer YL Liu, P Selenica, Q Zhou, A Iasonos, M Callahan, NZ Feit, J Boland, ... JCO precision oncology 4, 665-679, 2020 | 39 | 2020 |
| Imaging findings of immune checkpoint inhibitor associated pancreatitis JP Das, MA Postow, CF Friedman, RK Do, DF Halpenny European journal of radiology 131, 109250, 2020 | 33 | 2020 |
| A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. MM Rubinstein, I Caird, Q Zhou, A Iasonos, CF Friedman, KA Cadoo, ... Journal of Clinical Oncology 37 (15_suppl), 5582-5582, 2019 | 32 | 2019 |
